Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neur
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Source: GuruFocus